The primary aim was to develop all aspects of a robot-assisted human EBV-transformed, lymphoblastoid cell line facility within the ALSPAC population genetics laboratory in Bristol, so as to provide a reliable service for groups using large sample collections for human biomedical research. Once spare capacity arose following ALSPAC and 1958 Birth Cohort (58BC) work, this service was to be available, first, for selected Wellcome Trust funded research groups wishing to generate and bank cell lines, to use DNA from such cell lines or to study the cell lines themselves. A secondary aim was to learn more about the usefulness of EBV-transformed cell lines in genetic epidemiology beyond just providing a renewable source of DNA.